Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model

British Journal of Pharmacology

Volumn 135, Issue 6, 2002, Pages 1572-1578

  Ugawa, Tohru ^a   Kakuta, Hirotoshi ^a   Moritani, Hiroshi ^a   Shikama, Hisataka ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cholesterol; Escape phenomenon; HMG CoA reductase; Pravastatin; Squalene synthase; YM 53601

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SQUALENE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; YM 53601;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVITY; ENZYME ASSAY; EXPERIMENTAL MODEL; HAMSTER; HYPERCHOLESTEROLEMIA; LIPID DIET; LIVER CELL; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; REBOUND;

EID: 0036213753     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704595     Document Type: Article

References (21)

1. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
2. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: Comparison with inhibitors of HMG-CoA reductase
3. Azalanstat (RS-21607), a lanosterol 14-demethylase inhibitor with cholesterol-lowering activity
4. Hypocholesterolemic actions of atorvastatin are associated with alterations on hepatic cholesterol metabolism and lipoprotein composition in the guinea-pig
5. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
6. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats
7. Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats
8. Regulation of the mevalonate pathway
9. NB-598, a potent competitive inhibitor of squalene epoxidase
10. Protein measurement with the Folin phenol reagent
11. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo
12. Effects of simvastatin on the escape phenomenon following pravastatin therapy in patients with hypercholesterolemia
13. Therapy with HMG CoA reductase inhibitors: Characteristics of the long-term permanence of hypocholesterolemic activity
14. HMG-CoA reductase regulation: Use of structurally diverse first half-reaction squalene synthetase inhibitors to characterize the site of mevalonate-derived nonsterol regulator production in cultured IM-9 cells
15. Biosynthesis of non-head-to-tail terpenes. Formation of 1′-1 and 1′-3 linkages
16. Conversion of farnesyl pyrophosphate to squalene
17. Preparation of isolated rat liver cells
18. Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat
19. Dietary saturated triacylglycerols suppress hepatic low density lipoprotein receptor activity in the hamster
20. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects
21. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species